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Abstract 
Background: This work used mathematical modelling to explore effective policy for hepatitis C 
virus (HCV) treatment in Australia in the context of methadone maintenance treatment (MMT). 
Method: We consider two models to depict HCV in the population of injecting drug users (IDU) 
within Australia. The first model considers the IDU population as a whole. The second model 
includes separate components for those that are or are not enrolled in MMT. The impact of 
different levels of HCV treatment and its allocation dependent on MMT status were then 
determined in terms of the steady state levels of each of these models. 
Results: Although increasing levels of HCV treatment decrease chronic infection prevalence, 
initially numbers of acutely infected can rise. This is caused by the high rate of reinfection. We 
find that no matter the extent of HCV treatment, HCV prevalence cannot be eliminated without 
limiting risk behaviour. Assuming equal adherence to HCV therapy between MMT and non-
MMT, over 84% of HCV treatment should be allocated to those not in MMT. Only if adherence 
to HCV therapy in non MMT patients falls below 44% of that in MMT then treatment should be 
preferentially directed to those in MMT. 
Conclusions: Contrary to generally held beliefs regarding HCV treatment the majority of therapy 
should be allocated to those that are still actively injecting. This is due to rates of reinfection and 
to the high turnover of individuals in MMT. Higher adherence to HCV therapy in MMT would 
need to be achieved before this changed.  
 
Keywords: Hepatitis C; treatment; modelling  
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1. Introduction 
Hepatitis C virus (HCV) is a significant cause of morbidity and mortality with an estimated 170 
million people chronically infected globally (National Centre in HIV Epidemiology and Clinical 
Research, 2003). Injecting drug use (IDU) is a major risk factor for HCV infection, and the 
majority of injecting drug users in virtually all nations are HCV positive (Lelutiu-Weinberger et 
al., 2009; National Centre in HIV Epidemiology and Clinical Research, 2007). Between 70% and 
90% of acute HCV cases progress to chronic infection (Guidotti and Chisari, 2006). For those 
who receive treatment with pegylated interferon and ribavirin, approximately 50% will remain 
undetectable for HCV RNA 6 months post therapy (Novick and Kreek, 2008). However, HCV 
treatment is unpleasant and not necessarily well tolerated (Novick and Kreek, 2008). Moreover 
continued injecting behaviour places the user at risk of reinfection even if they successfully 
complete treatment (Aitken et al., 2008b). 
 
In these conditions, it is understandable that health practitioners may be reluctant to treat 
injecting drug users for HCV given concerns over poor compliance and the perceived risk of re-
infection (Hopwood and Treloar, 2007; Sylvestre, 2005). Both of these factors (compliance and 
risk of reinfection) can be significantly mitigated by methadone maintenance treatment (MMT) 
(Backmund et al., 2005). Compliance with HCV treatment can be enhanced through the daily 
MMT contact with treatment personnel, in addition to enhancing the initial referral into HCV 
treatment. Risk of reinfection can be reduced if the methadone treatment successfully reduces 
or eliminates injecting and other risk behaviour. It is therefore of interest to explore the dynamics 
of HCV infection, treatment and reinfection in the context of a drug treatment program such as 
MMT. 
 
This aim of this work was to use mathematical modelling to explore and draw some conclusions 
about effective policy for HCV treatment in the context of MMT and the likelihood of reinfection. 
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The extent to which all injecting drug users should receive treatment for Hepatitis C even if they 
continue to inject or engage in high risk behaviour is of policy interest because it will suggest 
how resources for HCV treatment could be distributed (between those in MMT and those 
outside MMT). It is also of ethical interest (Edlin et al., 2001). Importantly, the high rates of 
movement into and out of MMT (Bell and Burrell, 2006; Bell et al., 2006; Chalmers et al., 2009) 
may mean that the putative advantages incurred by the MMT population in being treated for 
HCV may largely disappear.  
2. Methods 
2.1 The Single Group Model 
We consider two mathematical models to depict HCV in the population of IDU.  The first model 
considers the IDU population without separation into those that are or are not enrolled in MMT.  
The model is depicted in Figure 1  where IDUs are separated into: the susceptible group  , 
individuals that are injecting but not infected; the acutely infected group  , individuals that have 
contracted HCV but have yet to pass to the chronic stage of the disease; the chronically infected 
group,  ; the HCV treatment group  ; and individuals who have recovered from HCV either 
spontaneously or through HCV treatment  . Given the short period of acute infection, and that 
this frequently goes undetected, only chronically infected individuals were assumed to enrol in 
HCV treatment. 
 
The governing equations for the first model are given in [1] 
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[1]  
where N is the total of the IDU population  
               
 
The terms in the first equation, which describe the rate of change in numbers of uninfected 
susceptible IDU, represent respectively: the influx of new users at rate   per year, the uninfected 
users contracting HCV due to sharing with acutely and chronically infected individuals    where 
          , users that have lost immunity at rate   after previously clearing the disease, 
and those IDUs in the susceptible group that exit the system due to cessation of risk behaviour 
or mortality at the rate  , per year (this same exit rate also applies to all other groups).  
 
The force of infection   is the rate at which susceptible individuals become infected with HCV 
through exposure to infected users. The force of infection includes the probability that an 
uninfected individual will become infected when sharing with HCV-infected individuals over the 
course of a year  . Its value is given by           . The parameter    is the number of 
days per year an IDU injects and shares, and p denotes the probability of getting infected each 
day of injecting and sharing, if sharing is with an HCV infected individual.  The infection rate   is 
multiplied by the proportion of infectious individuals in the total population reflecting the 
probability of having contact with an infected individual.   
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Other terms of note are the terms    and   , which represent those users infected with the 
disease that either spontaneously recover at the rate   per year or pass to the chronic stage at 
the rate   per year and the terms      and         , which represent those users that have 
entered treatment and succeed in clearing the disease with probability   or have failed 
treatment with probability    .  In both cases, these users leave HCV treatment at the 
respective rates    and     per year.   
 
We consider the rate at which HCV infected IDUs enter treatment to be dependent on the total 
population given by the treatment function 
(with   being the number of IDUs treated for HCV per year) instead of a treatment function with 
constant rate of detection and treatment,   ,   
The population dependent case [2] takes into account that there is a limited number of 
individuals in the total population and the relative effort of first finding IDUs before testing and 
subsequent HCV treatment (if positive). The two expressions give equivalent results for the 
steady-state results where       . 
2.2 The Two Group Model with MMT 
The second model separates the IDU population depending on whether individuals are enrolled 
in MMT.  We duplicate the structure of the Single Group model for individuals in MMT (subscript 
M), and those not in MMT (subscript N).  Users are assumed to be able to move between each 
group at rates   , the rate at which users move into MMT and    the rate at which users leave 
       
 
 
  [2]  
         .  
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MMT. The dynamics of the Two Group model are altered by two factors: 1) the rate of enrolment 
in MMT and 2) the relative likelihood of infection due to injecting risk behaviour (     ).  
 
The force of infection for users not in MMT is given by, 
      
                   
         
   [3]  
and for those in MMT treatment, 
      
                   
         
   [4]  
where    and    are the total populations of users in each group.  The forces of infection for 
both populations are in essence given by their respective chances of becoming infected through 
their different injecting/sharing rates,    and   .The corresponding equations for the Two 
Group model are   
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where we have used the same notation as in the Single Group model [1] but now with indices   
and   to denote the different groups.  We assume new IDU enter the susceptible group not in 
MMT   . 
2.3 Parameter Estimation 
We estimated parameters for the models based on IDU and HCV observations in Australia. 
These estimates are summarised in Table 1. The estimated number of new IDUs per year  , is 
4500 (Chalmers et al., 2009). The spontaneous recovery rate,  , and the progression rate to 
chronic infection  , can be estimated from observations that 25% of all HCV infected individuals 
clear infection within the first 6 months with the remainder progressing to chronic infection 
(Micallef et al., 2006; Razali et al., 2007). So we assume an average time in the acute state  , 
to be 6 months for all individuals.  A distinction must be made between those acutely and 
chronically infected IDUs to take into account the approximately 25% of those infected that clear 
the virus without treatment (Guidotti and Chisari, 2006). The annual rate of spontaneous 
recovery is then estimated as the inverse of the time in acute infection (in years) times the 
probability an individual clears infection (25%) which gives       per year.  The chronic 
progression rate   , is similarly estimated from the inverse of the time in acute infection times 
the probability an individual fails to clear infection 75%.  This leads to the parameter estimate 
     (year-1). 
 
In Australia, the annual HCV treatment rate is around 1% (Matthews, 2005). The length of HCV 
treatment is 24 weeks for Genotypes 2 and 3 and 48 weeks for Genotype 1 (Novick and Kreek, 
2008; Ostapowicz et al., 1999).  Hence we assume an average length of treatment of 36 weeks. 
We assume that if HCV treatment is successful the patient will stay for the entire course, and 
that those not successful adhere only half as well, so treatment is for an average period of 18 
weeks (Ostapowicz et al., 1999).  This leads to the rate    of those failing HCV treatment of 
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52/18 per year and the rate for    is 52/36 per year. The probability of success of HCV 
treatment   is approximately 50% (Novick and Kreek, 2008).  
 
HCV prevalence among IDUs in Australia is approximately 60% (National Centre in HIV 
Epidemiology and Clinical Research, 2007, 2008).  We take an estimate of incidence to be 20% 
per year (Matthews, 2005; Micallef et al., 2006). This is likely to be an overestimate, but is 
somewhat accommodated by our under-estimate of reinfection rate (see below). The number of 
new infections per year is therefore given by 
  
   
 
               
 so that   
   
   
     per year.  There is debate about the rate of reinfection in those that have 
previously cleared infection with estimates ranging from 2% to 47% per year (Aitken et al., 
2008a; Backmund et al., 2004; Grebely et al., 2006). We assume a reinfection rate, 
           of 5% per year thus       but acknowledge that new research suggests it is 
higher than this.  
 
The exit rate  , was determined from fitting the steady state prevalence,         of 60%.  
Assuming that current endemic steady state corresponds to the situation of 1% of the population 
of IDUs being treated for HCV (   =0.01) we estimate the exit rate to be roughly 0.083 per 
year.     
 
For the Two Group model, we assume that most of the parameters are the same as those for 
the Single Group model, with the exception being the infection rate  . We do not assume zero 
injecting whilst in MMT. We use data from Australian clinical trials on the number of days 
injecting out of MMT and within MMT: those within MMT on average inject approximately 8 fold 
less than those not enrolled in a program (Mattick et al., 2001; Moore et al., 2007; Teesson et 
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al., 2006). For values of   that are not too large,              . So an 8-fold higher 
sharing rate for those not in MMT would then provide a ratio of infection rates over the course of 
a year of approximately  
  
  
 
   
   
 
  
  
     . 
 By assuming 60% HCV population prevalence we obtain          and         compared 
to            for the Single Group model.  On average an individual stays in MMT for 8 
months, and stays out of treatment for an average of 12 months before re-entering (Chalmers et 
al., 2009), so        and     .  
 
2.4 Sensitivity Analyses 
Results described below are robust to parameter choices (Table 1). Sensitivity analyses 
revealed that the parameters that had the largest impact on steady state HCV prevalence were 
the rate of infection    , and the exit rate  , where changing these by      resulted in a 4-6% 
change in the predicted prevalence.  There was a smaller 3% change associated with the 
clearance probability   .  Perturbations of all other parameters by      , resulted in changes in 
steady state HCV prevalence of less that 1%. The sensitivity analysis for the Two Group model 
also determined that the infection rate of the non-methadone treatment group,   , and the exit 
rate (when varied equally between the groups),  , had the largest effect on the predicted steady 
state prevalence  (4-6%).   
3. Results  
3.1 Single Group Model 
Initially we consider the IDU population as a whole, without separation into whether individuals 
are enrolled in MMT or not. In this instance we investigate, on average, the impact on eventual 
HCV prevalence of increasing levels of HCV treatment. The eventual prevalence is determined 
from the steady state value of the mathematical model, and we denote outcomes in terms of 
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these steady state values. Of particular interest is the extent to which reinfection, for those that 
clear the infection either spontaneously or after successful HCV treatment, will negate any 
decreases in expected levels of HCV prevalence with expanded HCV treatment. The risk of 
HCV reinfection for active drug users has been one of the reasons promulgated for not 
providing HCV treatment to these individuals (Aitken et al., 2008b; Sylvestre, 2005).  
At current HCV treatment levels (1% of IDU, (Matthews, 2005; National Centre in HIV 
Epidemiology and Clinical Research, 2008) the model reproduces the expected 60% HCV 
prevalence. As increasing numbers of IDU are enrolled in HCV treatment, the percentage of 
chronically infected IDU decreases, with the fastest decrease in prevalence occurring for the 
earliest increases in treatment (see Figure 2). On the other hand the percentage of IDU with 
acute infection actually increases with small increases in treatment (Figure 2), before eventually 
decreasing as well. The fastest decrease in acute infection occurs at the highest treatment 
levels. Both chronic and acute HCV prevalence are estimated to eventually vanish at a 
treatment level of      56.5%.  
Although this critical treatment level eventually eliminates infection, it is slow to do so taking 3.3 
years for chronically infected numbers to decrease by half and 11.1 years for acute numbers to 
halve. Implementing this critical treatment level of      56.5% from current levels where HCV 
prevalence is 60%, and the majority of these in the chronic stage, would mean that initially 
56.5% of 60% so 33.9% of IDUs would be enrolled in HCV treatment. However as HCV 
treatment decreases prevalence, this treatment burden also decreases so that after 3 years 
when chronically infected numbers have halved, then the percentage enrolled in treatment at 
that time will also halve to 17%.  
The ability to eliminate HCV prevalence with suitably high levels of HCV treatment is calculated 
on parameter levels that duplicate the situation within Australia. It is dependent on rates of 
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needle sharing, contained within the infection term  , and this must be less than the rates at 
which acutely infected individuals leave this compartment,  
         
Since     , if sharing   is higher than this then no amount of testing and treatment will 
eradicate HCV infection. 
 
3.2 The Two Group model: the impact of MMT 
The previous analysis investigated the impact of increasing levels of HCV treatment on 
prevalence, without regard for changes in injecting/sharing when IDU are enrolled in MMT. The 
proportion of IDU enrolled in MMT can be substantial, with approximately 40,000 individuals 
currently enrolled in MMT in Australia (Australian Institute of Health and Welfare (AIHW), 2007). 
In this second model we divide the IDU population into two groups, those in MMT and who 
therefore inject/share approximately 8-fold less than those not in MMT. We now investigate two 
aspects of HCV treatment: how does treating   IDU each year impact on eventual HCV 
prevalence, and how is this best apportioned between individuals in MMT   , and those not in 
MMT   , (        ?  
 
Under the model parameter values the total population of IDU consists of 54,217 individuals, of 
which 20,990 are in MMT at any one time. If total treatment   amounts to 50% of all IDU then 
the minimum steady state HCV prevalence of 4.20% is reached if 84% (42%/50%) of HCV 
treatment is allocated to IDUs not enrolled in MMT while only 16% (8%/50%) is allocated to 
those in MMT. This is displayed in Figure 3 for those not in MMT: if 50% of the total population 
are treated, minimum steady state prevalence (vertical axis) is achieved when 42% of those not 
in MMT are treated (Figure 3).  In that situation 22,845 non-MMT individuals will be tested and 
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the resulting 782 chronically HCV-infected individuals will be treated, whereas 4,263 MMT 
individuals will be tested and 164 chronically infected individuals entered onto HCV therapy.  
 
This optimal allocation shifts between groups as levels of HCV treatment increase from their 
current 1% (Figure 4). At current treatment levels all therapy should be targeted to those not in 
MMT, but with increasing levels of HCV treatment a portion of this shifts to those enrolled in 
MMT (Figure 4). For the critical treatment level that theoretically eliminates HCV,        the 
optimal allocation is approximately 15% to those in MMT and the vast majority 85% to those not 
in MMT. 
 
In the previous calculations the only difference assumed between the two groups is that those in 
MMT are less likely to inject and share, and are therefore less likely to become HCV-infected. 
However achievement of a sustained virological response has been associated with less 
frequent drug use (Sylvestre, 2005). There is some debate about whether MMT increases 
compliance with HCV treatment (Ebner et al., 2009; Novick and Kreek, 2008; Treloar and 
Fraser, in press).  Therefore, if we assume that those not in MMT are less adherent to HCV-
treatment resulting in lower probability of success for this group (     ), then the optimal 
allocation point shifts to favour those in MMT. For the case of 50% treatment of all IDU, if those 
in the non-MMT group are only 48% as adherent to HCV therapy as those in MMT then 
allocation of HCV testing becomes equally distributed between groups. However even at this 
point there will be more individuals treated, rather than just tested, for HCV given the higher 
HCV prevalence in the non-MMT group. Of the model value of 33,227 individuals not in MMT, 
13,550 will be tested and the 2,090 of these who have chronic HCV will be treated. On the other 
hand only 1,919 MMT individuals will have chronic HCV and be treated. 
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Numbers entered into HCV therapy in each group will be the same (2,067 individuals) if 
adherence to HCV therapy in the non MMT group is only 44.3% of that in the MMT group. If 
adherence to HCV therapy in the non MMT group falls below 44.3% of that in the MMT group 
then the number tested and treated should be preferentially directed to those in MMT. 
 
4. Discussion and Conclusions 
Although increasing HCV treatment can lead to a relatively large decrease in chronically HCV-
infected IDU, HCV reinfection significantly impacts on the success of HCV treatment. The 
numbers acutely infected decay at a slow rate, as those that have previously been chronically 
infected re-enter the susceptible pool and become infected again. Contrary to expectations this 
results in higher levels of acute infection for small increases in treatment level.  
 
We have assumed that unlike human immunodeficiency virus (HIV) (Yerly et al., 2001), where 
viral loads are highest, acute HCV infection is not more infectious than chronic stage disease. 
Although viral loads are generally highest at acute HCV infection (Herring et al., 2005; Thimme 
et al., 2001), they generally do not experience a 100-fold decrease to chronic infection as seen 
in HIV (Murray et al., 1998). However if acute HCV infection is more infectious than chronic 
stage disease then it will exacerbate the rise in numbers acutely infected IDU when treatment 
increases, and will further slow the time taken to reduce HCV prevalence. 
 
Those acutely infected were included separately in the models since they can experience 
spontaneous clearance of HCV infection (Micallef et al., 2006). However those in the acute 
infection state did not enter HCV therapy in the model. . In Australia in 2006 diagnoses of acute 
HCV infection accounted for only 431 (3%) of a total of 12,526 HCV diagnoses in that year 
(National Centre in HIV Epidemiology and Clinical Research, 2007). The difficulty in identifying 
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acute HCV infection is a global problem with acute HCV infection in the United States in 2007 
representing 849 (5%) out of an estimated 17,000 new HCV infections (Centers for Disease 
Control and Prevention, 2009). However HCV treatment during acute infection can lead to 
higher rates of sustained virological response (Santantonio et al., 2008). Given that acute HCV 
infections are more likely to occur in individuals not enrolled in MMT, including the acute group 
in HCV treatment would further shift the preference towards the non-MMT group, although the 
change would not be substantial, given the difficulty in identifying this group. 
 
When HCV treatment is sufficiently high, approximately 60%, these models predict that HCV 
can be eliminated. Regardless of whether this is realistically feasible, our calculations underline 
the importance of programs that minimise the sharing of infected needles. If sharing is not 
effectively constrained, then no level of HCV treatment will be able to eliminate the epidemic, 
even in this simple theoretical setting. It emphasises the role that Needle Syringe Programs 
have had in containing HIV levels in Australian IDU, and in keeping HCV prevalence, although 
still high, at levels lower than other communities that have not invested as heavily in prevention 
(Murray et al., 2003). It also stresses that any push to expand HCV treatment must not be at the 
expense of preventative measures. 
 
It is difficult to accurately determine the rate of cycling in and out of MMT. While we use recent 
published estimates, these are averages across diverse populations and indeed, little is known 
about the rates of entry and exit and lengths of stay in MMT in Australia, because most research 
measures the proportion remaining in treatment at certain time points (3, 6 and 12 months). 
These do not easily convert to estimated duration in or out of MMT. We use population 
parameters of IDU, which are not necessarily heroin only (ie people inject amphetamines and 
are at risk of HCV infection through any injecting behaviour, not just opioids), and a treatment 
that is only for heroin (MMT). 
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Notwithstanding all these limitations, many of which are normal in the course of mathematical 
modelling (eg (Razali et al., 2007), this work represents the beginning of opportunities to 
explore, through mathematical modelling, ways in which policy on HCV treatment can be 
improved. Including more aspects of practical HCV treatment in a population over the long term, 
such as the spread of drug resistant virus and the impact of new treatment options such as HCV 
protease inhibitors, will be important components for the future. Although our model is simple, 
both in terms of the drug treatment (represented by MMT) and in terms of reinfection rate, it 
reveals some important potential policy implications: that we should be focusing our efforts on 
treating those with HCV in the community who continue to inject is perhaps at least a counter-
intuitive finding. Improved compliance with HCV therapy for those in MMT would need to be 
high to counteract our finding. Outcome studies are required to derive effect sizes on adherence 
and therapy success rates. Future models could then use these, providing greater precision in 
determining the optimal HCV therapy allocation. Changes to these important parameters 
(adherence, methadone turnover rates, HCV therapy outcomes) may lead to alternate 
conclusions from those derived here and may confer greater policy relevance to treating those 
within MMT over those in the community. 
 
The preferential targeting of HCV treatment to those not in MMT is partially a result of the 
continual recycling of IDUs in and out of MMT. Calculations with longer duration in MMT shift 
the optimal HCV treatment allocation more to those in MMT. So any measures that can lead to 
more sustained MMT will have a double effect: it will reduce the likelihood than an individual will 
continue to inject, and it will offer greater effectiveness of any HCV treatment. Especially if 
adherence is greater for those in MMT, retention of individuals in MMT can provide a multiplier 
effect on HCV treatment. Our results of the high proportion of HCV treatment targeted to 
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individuals who continue to inject may reflect the poor retention and cycling behaviour of 
patients within MMT rather than any inherent benefit of targeting active IDUs. 
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Table 1 Baseline Parameter Sources 
Parameter Definition Value 
  Number of users starting injecting (per year) 4500  
  Spontaneous recovery rate (per year) 0.5  
  Rate of progression to chronic state C (per year) 1.5  
   Probability of clearing acute infection 25% 
    Duration of Acute infection (years) 1/2 
    Duration of HCV treatment if succeeding (weeks) 36 
    Duration of HCV treatment if failing (weeks) 18 
   Rate of leaving HCV treatment  when failing (per year) 52/18 
   Rate of leaving HCV treatment when succeeding (per year) 52/36 
  Probability of success of HCV treatment  50% 
  
Rate of infection due to sharing (per year per contact with an infected 
individual) 
1/3 
  Rate of individuals leaving the R state (per year) 1/4 
   Percentage of individuals on HCV treatment (per year) 1% 
  Number of individuals entering HCV treatment (per year) 539.362 
  Exit rate per year 0.083 
   
Rate of infection of IDUs (not in MMT) due to sharing (per year per 
contact with an infected individual) 
0.503 
   
Rate of infection of IDUs (in MMT) due to sharing (per year per 
contact with an infected individual) 
0.060 
   
Number of HCV infected IDUs entering treatment not in MMT (users 
per year) 
332.270 
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   Number of HCV infected IDUs entering treatment in MMT (per year) 209.899 
  
  
Number of HCV infected IDUs entering treatment not in MMT (per 
year) 
1% 
  
  Number of HCV infected IDUs entering treatment in MMT (per year) 1% 
    Duration in MMT (months) 8 
   Rate of leaving MMT (per year) 3/2 
    Duration out of MMT (months) 12 
   Rate of entering methadone treatment  (per year) 1 
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Figure Legends 
 
Figure 1: Single Group Model. 
    
Figure 2  The effect of the treatment rate (percentage of the total population per year),  , on the 
percentage of acutely infected,   , (left) and chronically infected,  , (right) users in the endemic 
steady state.  
 
Figure 3 The estimated HCV prevalence in the endemic steady state is lowest (4.2%) when 
42% of those not in MMT receive HCV treatment (   N) if we treat 50% of the total population. 
        
Figure 4 The effect of varying the percentage of the total population treated per year on the 
optimal treatment allocation between non-methadone (solid line) and methadone (dashed line) 
participants. 
 
 
 
